


REMARKS

Claims 1-20 were filed in the accompanying Continuation Application. The above amendment cancels Claims 1-20, and adds new Claims 21-44. As such, Claims 21-44 are currently pending in this Application.

Dated: December 21, 2001



Jason R. Bond
Registration No. 45,439
MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
608-218-6900

10036819 " 122101

PENDING CLAIMS

21. A method of treatment, comprising:
- a) providing:
 - i) a subject with symptoms of an inflammatory bowel disease, wherein said inflammatory bowel disease is selected from the group consisting of ulcerative colitis and crohn's disease, and
 - ii) a therapeutic composition comprising a biologically active vitamin D compound, wherein said biologically active vitamin D compound is 1α -hydroxyvitamin D₃; and
 - b) administering a therapeutically effective amount of said therapeutic composition to said subject under conditions such that said symptoms are reduced.
22. The method of Claim 21, wherein said therapeutically effective amount comprises a daily dose of between 0.1 μ g and 20 μ g per 160 pounds of said subject.
23. The method of Claim 21, wherein said therapeutically effective amount comprises a daily dose of between 0.5 μ g and 10 μ g per 160 pounds of said subject.
24. The method of Claim 21, wherein said therapeutically effective amount comprises a daily dose of between 3.0 μ g and 10 μ g per 160 pounds of said subject.
25. The method of Claim 21, wherein said administering is conducted in a continuous manner.
26. The method of Claim 21, wherein said administering is via a transdermal patch.
27. The method of Claim 21, wherein said administering is via a suppository.
28. The method of Claim 21, wherein said administering is via a slow release oral formulation.

29. A method of treatment, comprising:
- a) providing:
 - i) a subject with symptoms of an inflammatory bowel disease, wherein said inflammatory bowel disease is selected from the group consisting of ulcerative colitis and crohn's disease, and
 - ii) a therapeutic composition comprising a biologically active vitamin D compound, wherein said biologically active vitamin D compound is 1α -hydroxyvitamin D₂; and
 - b) administering a therapeutically effective amount of said therapeutic composition to said subject under conditions such that said symptoms are reduced.
30. The method of Claim 29, wherein said therapeutically effective amount comprises a daily dose of between 0.1 μ g and 20 μ g per 160 pounds of said subject.
31. The method of Claim 29, wherein said therapeutically effective amount comprises a daily dose of between 0.5 μ g and 10 μ g per 160 pounds of said subject.
32. The method of Claim 29, wherein said therapeutically effective amount comprises a daily dose of between 3.0 μ g and 10 μ g per 160 pounds of said subject.
33. The method of Claim 29, wherein said administering is conducted in a continuous manner.
34. The method of Claim 29, wherein said administering is via a transdermal patch.
35. The method of Claim 29, wherein said administering is via a suppository.
36. The method of Claim 29, wherein said administering is via a slow release oral formulation.

37. A method of treatment, comprising:
- a) providing:
 - i) a subject with symptoms of an inflammatory bowel disease, wherein said inflammatory bowel disease is selected from the group consisting of ulcerative colitis and crohn's disease, and
 - ii) a therapeutic composition comprising a biologically active vitamin D compound, wherein said biologically active vitamin D compound is 19-nor-1 α ,25-dihydroxyvitamin D₂; and
 - b) administering a therapeutically effective amount of said therapeutic composition to said subject under conditions such that said symptoms are reduced.
38. The method of Claim 37, wherein said therapeutically effective amount comprises a daily dose of between 0.1 μ g and 20 μ g per 160 pounds of said subject.
39. The method of Claim 37, wherein said therapeutically effective amount comprises a daily dose of between 0.5 μ g and 10 μ g per 160 pounds of said subject.
40. The method of Claim 37, wherein said therapeutically effective amount comprises a daily dose of between 3.0 μ g and 10 μ g per 160 pounds of said subject.
41. The method of Claim 37, wherein said administering is conducted in a continuous manner.
42. The method of Claim 37, wherein said administering is via a transdermal patch.
43. The method of Claim 37, wherein said administering is via a suppository.
44. The method of Claim 37, wherein said administering is via a slow release oral formulation.